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Introduction
Measurement of glycosylated haemoglobin (HbA1c)
has been the focus of managing patients with type 2
diabetes for many years. Based on the outcomes of
several landmark studies (1–4), guidelines for good
glycaemic control have been agreed upon and a
patient is generally considered to have achieved suc-
cessful disease control when their HbA1C is < 7%
(5–7). Management of the patient with type 2 diabe-
tes requires continuous monitoring and currently
this may involve occasional measurement of fasting
plasma glucose as an indicator of the efﬁciency of
the body in regulating glucose levels in the absence
of dietary glucose. However, better understanding of
the pathophysiology underlying type 2 diabetes has
indicated that control of fasting plasma glucose levels
is not critical in early stage disease (8). In addition,
fasting plasma glucose does not correlate well with
HbA1C (9,10), suggesting that there may be other
factors that make a signiﬁcant contribution to overall
glycaemic control. Recent evidence (11) has high-
lighted the role of postprandial glucose levels and
associated glycaemic variability in achieving and
maintaining comprehensive glycaemic control in
patients with type 2 diabetes.
Changing the paradigm
Over the years, target HbA1C levels have been the
subject of much debate, but until recently, it has
been accepted that HbA1C should be as low as is
realistically achievable. The strategy of ‘the lower, the
better’ was reinforced by data from the UK Prospec-
tive Diabetes Study (UKPDS) that showed that any
reduction in HbA1C in patients with type 2 diabetes
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doi: 10.1111/j.1742-1241.2010.02517.x 1705is likely to reduce the risk of complications, with the
lowest risk being in those with HbA1C values < 6%
(1).
However, more recent studies have raised con-
cerns that intensive treatment and stringent HbA1C
targets may be detrimental in some patients. The
Action to Control Cardiovascular Risk in Diabetes
(ACCORD) trial was stopped early when it was
found that there was an increased risk of death in
patients who received intensive blood glucose-lower-
ing therapy with an HbA1C target of < 6% (12).
Patients who experienced severe hypoglycaemia were
at increased risk of death regardless of whether they
were receiving intensive or standard treatment (13).
Moreover, both ACCORD (12) (target HbA1C < 6%)
and the Action in Diabetes and Vascular Disease:
Preterax and Diamicron Modiﬁed Release Controlled
Evaluation (ADVANCE) (14) (target HbA1C < 6.5%)
trials failed to show that achievement of good gly-
caemic control was associated with reduction of car-
diovascular risk. These ﬁndings appear to be
supported by results from a new retrospective cohort
study that was conducted in the UK (15). Patients
with type 2 diabetes whose glucose-lowering treat-
ment had been intensiﬁed were identiﬁed from gen-
eral practitioner records. Low and high HbA1C levels
were associated with increased mortality and cardiac
events, with the lowest risk seen at an intermediate
HbA1C of 7.5%. This study did have several
limitations, including failure to take into account
concomitant therapy for cardiovascular disease, non-
standardised measurement of HbA1C and missing
data. In addition, the study was conducted in the
UK where general practitioners are encouraged to
pay more attention to patients with HbA1C >7 %
than to those who are better controlled. Neverthe-
less, the study has contributed further to the current
debate and discussion.
Most patients with type 2 diabetes are still failing
to achieve adequate glycaemic control and the dis-
ease remains a major cause of morbidity and mortal-
ity (16–19). But the conundrum remains: if driving
HbA1C down to lower target levels is not the answer,
what other factors involved in glucose homeostasis
can or should be targeted? For several years, the
related phenomena of daily plasma glucose variability
and postprandial glucose levels have been under
scrutiny, particularly in relation to HbA1C and fast-
ing plasma glucose. Although their position in the
so-called glucose triad is gaining acceptance (Fig-
ure 1) (20–23), there is ongoing debate regarding the
contribution of postprandial glucose levels to overall
glycaemic control and the role of postprandial glu-
cose targets in the management of a patient with
type 2 diabetes.
Comprehensive glycaemic control –
the role of postprandial glucose and
glucose variability
In individuals with normal glucose tolerance, the
plasma glucose concentrations generally rise no
higher than 7.8 mmol⁄l after a meal and return to
normal levels within 2–3 h. In contrast, in individu-
als with type 2 diabetes, postprandial plasma glucose
levels > 7.8 mmol⁄l are common, even in those who
are considered to have good overall glycaemic con-
trol according to measurement of HbA1C (Figure 2).
In fact, achievement of target HbA1C and fasting
plasma glucose levels does not necessarily indicate
that good glycaemic control is continuous through-
out the day.
Type 2 diabetes is a progressive disease. The typi-
cal course is initially a gradual loss of glycaemic
control after meals, followed by the development of
fasting hyperglycaemia in the morning and ﬁnally
sustained hyperglycaemia during the night. Patients
HbA1c
Average long-term
glucose level
Fasting
glucose
Postprandial
glucose
Figure 1 HbA1C, postprandial glucose and fasting plasma
glucose interrelate and are essential targets for intervention
in attempts to optimise overall glycaemic control. This
ﬁgure was published in Diabetes and Metabolism; 32:
Special Issue no 2. Monnier L, Colette C, Boniface H,
Contribution of postprandial glucose to chronic
hyperglycaemia: from the ‘‘glucose triad’’ to the trilogy of
‘‘sevens’’. 2S11–2S16, Copyright Elsevier 2006
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Figure 2 Blood glucose proﬁle over 24 h in an individual
with type 2 diabetes
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yet developed type 2 diabetes tend to have near
normal fasting plasma glucose, but show variable
glucose excursions after the three meals of the day
(24). The key pathological effect at this prediabetes
stage is loss of ﬁrst phase insulin secretion. This is
the early surge of insulin that occurs within 5 min
of eating and is critical for suppression of hepatic
glucose production and priming the liver and
peripheral tissues, particularly muscle and fat, for
glucose uptake (Figure 3).
The onset of frank type 2 diabetes is characterised
by a progressive decline in insulin sensitivity together
with progressive deterioration in beta-cell function
leading to reduced insulin secretion. Increased fasting
plasma glucose levels in patients with type 2 diabetes
are largely attributable to reduced hepatic sensitivity
to insulin leading to overproduction of glucose by
the liver during the overnight fast (25). As diabetes
progresses, these effects persist into the morning and
result in particularly marked hyperglycaemia follow-
ing breakfast (8).
In contrast to fasting hyperglycaemia, the causes of
postprandial hyperglycaemia are much more com-
plex. Postprandial glucose levels are inﬂuenced by
the blood glucose level before the meal and the glu-
cose load from the meal, as well as physiological fac-
tors such as insulin secretion and insulin sensitivity
in the peripheral tissues. The incretin hormones, glu-
cagon-like peptide (GLP)-1 (Table 1) (26) and gas-
tric inhibitory polypeptide (GIP) are released by the
intestine in response to ingestion of carbohydrate.
These hormones enhance insulin secretion, suppress
hepatic glucose production and decrease gastric emp-
tying and have a greater effect on postprandial glu-
cose levels than fasting glucose levels. Patients with
type 2 diabetes have reduced levels of the incretin
hormones.
It is important to understand the relationships
between HbA1C, and fasting and postprandial blood
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Figure 3 The role of GLP-1 and GIP in glucose homeostasis. Key defects in individuals with type 2 diabetes are shown in
red circles
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the disease, if type 2 diabetes is to be managed opti-
mally. Fasting and postprandial plasma glucose both
contribute to HbA1C. However, the relative contribu-
tion of these two factors depends on the HbA1C
level, with postprandial glucose contributing rela-
tively more at lower HbA1C levels (27,28). Early in
the course of the disease, when fasting plasma glu-
cose levels are near normal, postprandial glucose is
more important in determining HbA1C. Measure-
ment of 24-h plasma glucose proﬁles in patients with
HbA1C of < 6.5%, ‡ 6.5% to < 7% and ‡ 7% to
< 8% showed that fasting plasma glucose levels were
very similar in these three groups, with the principal
difference being in postprandial glucose (Figure 4)
(8). These data suggest that reduction of HbA1C in
patients who are close to target (< 8%) is best
achieved by speciﬁcally targeting postprandial glucose
levels. As glucose control deteriorates and HbA1C
rises, the contribution of fasting plasma glucose
becomes more signiﬁcant. In groups of patients with
HbA1C of ‡ 8% to < 9% and ‡ 9%, fasting plasma
glucose progressively increased, indicating that
control of both fasting and postprandial glucose is
important at these higher HbA1C levels (Figure 4) (8).
Short-term glucose ﬂuctuations or spikes may also
have important clinical implications. Plasma glucose
excursions following a meal are generally greater, last
longer and are more variable in patients with type 2
diabetes compared with the normal population
(Figure 5). A recent review of all available evidence
suggested that variability in plasma glucose levels
may be an independent risk factor for the develop-
ment of microvascular and macrovascular complica-
tions and mortality (29). Smoothing the daily
glucose proﬁle by reducing the amplitude of glucose
spikes may result in improved overall glycaemic con-
trol and thus a theoretical reduction in the associated
complications.
Potential adverse effects of elevated
postprandial glucose
The speciﬁc relationship between postprandial
hyperglycaemia and the development of diabetic
complications is unclear. Postprandial hyperglyca-
emia does appear to be correlated with the risk of
Table 1 Actions of glucagon-like peptide 1 (26)
Brain Induces feeling of satiety
Reduces food intake
Gastro
intestinal
tract
Delays gastric emptying
Delays food absorption
Pancreas Stimulates glucose-dependent insulin
secretion
Suppresses glucagon secretion
Increases beta-cell sensitivity
Increases beta-cell mass (animal studies
only)
Liver Decreases hepatic glucose output because
of reduced glucagon secretion
Fat⁄muscle Stimulates glucose uptake
Heart Increases myocardial protection
Improves endothelial function
Decreases blood pressure
Improves left ventricular function
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Figure 4 The 24-h recordings from a continuous glucose monitoring system in ﬁve groups of patients with type 2
diabetes. Blue: HbA1C < 6.5%; red: ‡ 6.5% to < 7%; green: ‡ 7% to < 8%; orange: ‡ 8% to < 9%; purple: ‡ 9%.
Reproduced with permission from Monnier L et al. Diabetes Care 2007;30:263–9
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evidence suggesting that raised postprandial glucose
may be an independent risk factor for macrovascular
complications, particularly for cardiovascular disease,
but as this is still the subject of intensive research,
no deﬁnitive conclusions can be drawn (30–35).
Epidemiological data suggest that postprandial
hyperglycaemia is a risk factor for the development of
cardiovascular diseases, but there remains a need for
evidence that lowering postprandial hyperglycaemia
will help prevent cardiovascular disease. Results
from the Study to Prevent Non-Insulin-Dependent
Diabetes Mellitus (STOP-NIDDM) trial, in which the
impact of postprandial hyperglycaemia was evaluated
as a predeﬁned secondary end point, suggest that
treating postprandial hyperglycaemia may reduce the
incidence of new cardiovascular events in people with
impaired glucose tolerance (36). This ﬁnding was sup-
ported by a meta-analysis on the use of acarbose in
patients with type 2 diabetes (37). However, the
Hyperglycaemia and its Effect after Acute Myocardial
Infarction on Cardiovascular Outcomes in Patients
With Type 2 Diabetes (HEART2D) study (35) and the
Nateglinide and Valsartan in Impaired Glucose Toler-
ance Outcomes Research (NAVIGATOR) study in
those with impaired glucose tolerance (38) both failed
to conﬁrm this ﬁnding. The HEART2D study did not
reach the predetermined difference in postprandial
blood glucose of 2.5 mmol⁄l between patients
randomly assigned to prandial or basal strategies; the
mean difference between the two groups at the end of
the study was 0.8 mmol⁄l, less than one-third of the
goal, even though the difference was signiﬁcant (35).
In the NAVIGATOR trial, not only did nateglinide
not improve postprandial hyperglycaemia, but glucose
levels 2 h after an oral glucose challenge were higher
in the nateglinide group than in the placebo group
(38). Furthermore, the incidence of new diabetes was
slightly higher in the nateglinide-treated group than
in the placebo group (36.0% vs. 33.9%) – although
this was not statistically signiﬁcant – and nateglinide
also increased the risk of hypoglycaemia.
There were, however, a number of potentially con-
founding factors in the NAVIGATOR study, which
mean that these results have only added to the ongo-
ing debate. It is important to be aware of the level of
cardiovascular risk of patients included in clinical
studies (33). Although data suggest that the control
of hyperglycaemia may have a different impact on
primary and secondary prevention of cardiovascular
disease in patients with type 2 diabetes, in the NAVI-
GATOR study, patients in these two groups were
pooled and evaluated together (38). A further con-
cern is the very high dropout rate.
What does seem to be more certain, however, as
recent lessons from ACCORD (39,40), ADVANCE
(41), Veteran’s Affairs Diabetes Trial (VADT) (42)
and from the long-term follow-up of the UKPDS
(43) suggest, is that if the control of hyperglyca-
emia, whether fasting (ACCORD, ADVANCE,
VADT) or postprandial (35), is started too late, the
possible beneﬁcial effect of treatment that is initi-
ated in a very early stage of the disease is lost
(2,36).
Impact of HbA1c, fasting plasma
glucose and postprandial glucose on
management approaches and
treatment choice
Early and sustained control of glycaemia is important
in the management of type 2 diabetes. Many patients
do not reach HbA1C targets set according to pub-
lished guidelines (16–19). Following publication of
ACCORD, ADVANCE and other studies (12,15,44),
management guidelines are moving towards a
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Figure 5 Individual 24-h recordings from a continuous glucose monitoring system in four patients with type 2 diabetes on
insulin therapy and a mean HbA1C of 6.7%
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upon individual goals with each patient taking into
account age, comorbidity, personal circumstances and
attitudes, etc. (45). Regardless of the HbA1C goal that
is agreed upon, it is unlikely to be reached unless both
fasting and postprandial glucose levels are adequately
controlled, ideally through a combination of lifestyle
modiﬁcation and appropriate drug therapy.
All people who are living with diabetes should be
given information and education that are tailored to
their individual needs. Lifestyle modiﬁcations are an
important part of the treatment plan and can also
help to reduce postprandial hyperglycaemia. In par-
ticular, altering the quantity and composition of the
meal and taking regular exercise can be beneﬁcial
(46). Foods with a lower glycaemic index contain
carbohydrates that are more slowly digested and
absorbed. There is some evidence that diets with a
low glycaemic load are beneﬁcial in reducing post-
prandial glucose excursions (47).
Routine measurement of postprandial glucose lev-
els is not currently recommended or even practical
for all patients with type 2 diabetes. However,
improved understanding of the relative inﬂuence of
fasting and postprandial glucose levels throughout
the course of the disease might inﬂuence the class of
drug that is prescribed. Recent research has suggested
that intensiﬁcation of glucose control with insulin
therapy may not be advisable for all patients with
type 2 diabetes and oral antidiabetic drugs should be
used for as long as possible (15). International Dia-
betes Federation (IDF) guidelines for the manage-
ment of postmeal (postprandial) glucose state that
the goal of diabetes therapy should be to achieve gly-
caemic status as near to normal as safely possible in
all three measures of glycaemic control, namely
HbA1C, fasting premeal glucose and postmeal glucose
(47). Treatment of both fasting and postprandial
hyperglycaemia should be initiated simultaneously at
all levels of HbA1C above agreed levels. Traditional
treatments such as metformin and thiazolidinediones
primarily lower fasting plasma glucose. As sulpho-
nylureas are generally taken in the morning, they do
lower postprandial glucose levels during the day and
subsequently have an effect on overnight fasting
levels. Therapeutic agents are available that preferen-
tially lower postprandial glucose, including alpha-
glucosidase inhibitors, glinides, incretin mimetics,
dipeptidyl peptidase (DPP)-4 inhibitors and rapid-
acting insulins. An ideal approach to the treatment
of a patient with newly diagnosed type 2 diabetes
might be to start with the combination of metformin
and a DPP-4 inhibitor. This combination effectively
targets the two key pathophysiological features of
type 2 diabetes: loss of ﬁrst phase insulin secretion
and insulin resistance. Combination of a DPP-4
inhibitor with metformin is likely to be better toler-
ated than combination with a sulphonylurea, with a
lower incidence of weight gain and a very low risk of
hypoglycaemia (48).
Conclusions
It is becomingly increasingly clear that physicians are
likely to have to consider plasma glucose levels both
after the overnight fast and after meals in order to
achieve optimal glycaemic control for each patient.
The optimal glycaemic control equation equates to
HbA1C (at target) + fasting plasma glucose (to tar-
get) + postprandial glucose (to target) without hypo-
glycaemia and weight gain. Although target HbA1C
levels can be reached by lifestyle modiﬁcation
together with combination drug therapy, optimal
glycaemic control may be best achieved by selection
of agents that target both fasting and postprandial
hyperglycaemia.
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